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Abstract: Vesicovaginal fistulas are devastating conditions for the affected women. The combination of a
hysterectomy and radiation increases the fistula risk 5-10 times. Radiation-induced recurrent vesicovagi-
nal fistulas have the lowest success rate and require the most demanding treatment. We present the case
of a recurrent post-radiation vesicovaginal fistula treated with a small intestine graft after unsuccessful
conservative and failed previous operative treatments. The surgical management with a small intestine
graft led to a permanently closed fistula. We describe the surgical abdominal procedure step-wise and
review the rather scarce, post-radiation fistula literature. The closure of a vesicovaginal fistula with a
small intestine graft is a complex surgical treatment with a long-term, successful result.
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The aim of this study was to analyze the clinical experience and outcome of patients who 3 
have undergone pelvic exenteration for primary advanced or recurrent endometrial cancer. 4 
Methods: 5 
We analyzed the medical records of 40 women who underwent pelvic exenteration to treat 6 
primary advanced or recurrent endometrial cancer. 7 
Results: 8 
Pelvic exenteration was performed in 40 patients with primary advanced or recurrent 9 
endometrial cancer. Three patients (8%) underwent a primary exenteration, and 37 patients 10 
(92%) underwent a secondary exenteration. A total exenteration, anterior exenteration, and 11 
posterior exenteration was performed in 85%, 5% and 10% of patients, respectively. 12 
In 31 cases, exenteration was performed with a curative aim, and in 9 cases, exenteration was 13 
performed with a palliative aim. The overall survival rates were 61.4% at five years and 14 
51.1% at 10 years. For the 31 patients who underwent pelvic exenteration with a curative aim, 15 
the overall survival rates were higher than those for the entire study population and were 72.6 16 
% at five years and 59.4 % at 10 years. For the nine patients that underwent a palliative 17 
exenteration, the overall survival rates were 19.1 % at five years and 0 % at 10 years. This is 18 
to the best of our knowledge the biggest study of pelvic exenteration in patients with 19 
endometrial cancer 20 
Conclusion:  21 
Our data show that pelvic exenterations are a valid therapeutic option with long-term survival 22 
in select patients.  23 
 24 





Pelvic exenteration has been performed since December 1946 and describes a surgical 28 
procedure that involves the en bloc removal of reproductive organs, the bladder with the 29 
urethra, the pelvic ureter, the rectum and the sigmoid colon, including the anus and perineum. 30 
Alexander Brunschwig characterized the procedure in his article as, “the most radical surgical 31 
attack so far described for pelvic cancer”. The perioperative mortality rate at the time that 32 
article was published was 23%, and long-term survival rates were low [1]. 33 
Due to substantial improvements in operative and reconstructive techniques, the mortality and 34 
morbidity rates of pelvic exenteration have decreased and its survival rate is continuously 35 
increasing. The improvements to this technique have enhanced patient quality of life.Thus, 36 
the role of pelvic exenteration has been reconsidered in recent years. 37 
Currently, pelvic exenteration is absolutely considered as a treatment option for select patients 38 
with advanced gynecologic malignancies. These patients have often suffered a recurrence 39 
after either operation, irradiation or both. The cancer that is most frequently treated with 40 
pelvic exenteration is cervical cancer, and all other gynecologic malignancies are less 41 
commonly treated by this radical operation. 42 
The aim of this study was to analyze the outcome of patients who have undergone pelvic 43 
exenteration for primary advanced or recurrent endometrial cancer. These patients are 44 
normally older than patients with cervical cancer and, therefore, often have numerous 45 
comorbidities. Thus, the decision to perform pelvic exenteration is made highly restrictively. 46 
Our data indicate that despite of these problems, pelvic exenteration for primary advanced or 47 
recurrent endometrial cancer is an option that is feasible with high survival rates and, 48 






Patients and methods 53 
We retrospectively analyzed the medical records of 40 patients who underwent pelvic 54 
exenteration due to primary advanced or recurrent endometrial cancer.  55 
Exenteration was indicated as the primary treatment when the uterine tumor had infiltrated the 56 
bladder and/or rectum inducing fistulas. The majority of cases were secondary exenterations 57 
performed after an initial operation with or without irradiation treatment; in those cases, the 58 
indication for exenteration was tumor recurrence that met the criteria for primary 59 
exenteration.   60 
All 40 patients underwent a preoperative examination under general anesthesia to verify the 61 
presence of a tumor histologically and to evaluate the tumor’s operability. This examination 62 
also included a cystoscopy and rectoscopy. Additionally, a computerized tomography (CT) 63 
scan was performed.  64 
If the CT scan showed no evidence of metastasis, no intraabdominal metastases were found 65 
during the operation and clear margins were pathologically confirmed, the exenteration was 66 
considered curative. An exenteration was considered palliative in cases with distant 67 
metastasis, a positive peritoneal lavage or tumor perforation into the pouch of Douglas, and 68 
when positive margins were detected pathologically. 69 
Among the 40 patients, 12 women (30%) had comorbidities, including four with hypertonia, 70 
two with diabetes or severe obesity, one with nicotine abuse and three with multiple 71 
comorbidities (Table 1). 72 
All exenterations were performed at the Department of Gynecology of the General Hospital 73 
Neumarkt and the Department of Gynecologic Oncology of the University Hospital Erlangen. 74 
In total, seven surgeons were involved in this study. 75 
Anterior exenteration was defined as the removal of the uterus and vagina with the bladder, 76 
the pelvic ureters and the urethra, and posterior exenteration was defined as the removal of the 77 
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reproductive tract with the recto-sigmoid colon. Total exenteration included the removal of 78 
both the anterior and posterior compartments. 79 
Reconstruction included the formation of a continent ileocecal bladder (30/40) whenever 80 
possible; otherwise, conduits (4/40) and uretero-uretero-stomas (2/40) were constructed. In 81 
addition, 30 colonic neovaginas were generated using the caudal 10 cm of the colon above the 82 
resection. This portion of the colon was divided from the rest of the colon to preserve its 83 
blood supply and was then rotated 180°. Furthermore, the omental flap was used in 32 cases 84 
to provide much better pelvic filling, and this reduced the specific morbidity. Of the 40 85 
patients, 31 (78 %) received complete continent reconstruction.  86 
To restore bowel continuity, 37 colorectal or coloanal anastomoses were performed. In cases 87 
with high irradiation doses or extremely deep anastomosis, a temporary protective stoma was 88 
built for six weeks (16/40). Three patients required a permanent colostomy.  89 
The survival analysis was performed using Kaplan-Meier curves and Greenwood 95% 90 
confidence bands. Survival curves were compared using the log-rank test. Fisher’s exact test 91 
was used to examine the significance of the association between two variables in a 2 x 2 92 
contingency table. 93 
 94 
Results 95 
Pelvic exenteration was performed in 40 patients with primary advanced or recurrent 96 
endometrial cancer. Three patients (8%) underwent a primary exenteration, and 37 patients 97 
(92%) underwent a secondary exenteration. For the secondary exenteration cases, the disease-98 
free period from initial treatment to the time of exenteration ranged from 4 to 111 months, 99 
with a median of 24 months, and 32% (12/37), 3% (1/37) and 65% (24/37) of those patients 100 
had been pretreated with surgery alone, irradiation alone, and a combination of surgery and 101 
irradiation, respectively. Two patients in the latter group also received chemotherapy. Out of 102 
the 36 patients that were surgically pretreated, 13 underwent lymphadenectomy, and of those 103 
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13 patients, nine were nodal negative, and three had lymph node metastases; for the remaining 104 
patient, no histological record was found. 105 
Of the 40 patients included in this study, two (5%), four (10%) and 34 (85%) underwent an 106 
anterior, posterior and total exenteration, respectively. In 31 cases (78%), exenteration was 107 
performed with a curative aim, and in 9 cases (23%), exenteration was performed with a 108 
palliative aim. 109 
The median patient age was 63.5 years with a range of 43 to 78 years. The mean follow up 110 
time after exenteration was 51 months, with a median of 35 months and a range of 1 to 263 111 
months. 112 
A lymphadenectomy was performed in 37 patients, and three patients in the secondary 113 
exenteration group had not undergone a lymphadenectomy. Two, four, and 31 patients had 114 
undergone pelvic, paraaortic and both pelvic and paraaortic lymphadenectomies, respectively. 115 
Additional interventions, such as nephrectomy (3 cases), removal of small bowel sections (7 116 
cases), removal of colon sections (3 cases) and vulvectomy (2 cases), were performed when 117 
necessary.  118 
Eight patients (20%) were found to have distant metastasis. Of the patients with a single 119 
metastasis, two had a metastasis in the abdominal wall and one each had a metastasis in the 120 
ovary, inguinal lymph nodes, mesentery and paravaginal tissue. Two patients showed multiple 121 
metastases intraoperatively. 122 
The tumors were grade 1 in four cases (10%), grade 2 in 14 cases (35%) and grade 3 in 20 123 
cases (50%). In two cases (5%), only post-irradiation scarring was found without evidence of 124 
a tumor. In 29 patients (73%), the tumor entity was an adenocarcinoma.  125 
In 37 patients (92%), a pathological complete removal of the tumor was achieved, and three 126 
patients (8%) had positive margins. Two out of those 3 patients (66%), whom had undergone 127 
a primary exenteration, had clear margins. Clear margins were also found in 95% of patients 128 
(35/37) who underwent a secondary exenteration.  129 
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In 27 cases, no lymph node metastases were found. Two patients were positive for pelvic 130 
lymph node metastases and one patient was positive for paraaortic lymph node metastases. 131 
Additionally, seven patients were positive for both pelvic and paraaortic nodal metastases. 132 
Two of those patients (29%) had undergone a primary exenteration (Tab. 2).  133 
The 30 patients with pathologically free lymph nodes had a 5-year survival rate of 63.3% and 134 
a 10 year survival rate of 57.0%.  135 
The overall survival rate was 61.4% at 5 years and 51.1% at 10 years (Fig. 1). For the 31 136 
patients who underwent pelvic exenteration with a curative aim, the overall survival rates 137 
were higher than those for the entire study population and were 72.6% at 5 years and 59.4% at 138 
10 years (Fig. 2).  139 
For the 9 patients that underwent a palliative exenteration, the survival rate was 19.1 % at five 140 
years and 0% at 10 years (Fig. 2). Two of those 9  patients died, one at 2 months after 141 
exenteration due to sepsis and one due to general weakness. Three patients died due to distant 142 
pulmonary metastasis, and one patient died due a new tumor recurrence. Three patients, who 143 
were all at least 60 years old, were lost to follow-up after five, eight and 108 months.  144 
The patients that were 43 to 55 years of age (8, 20%) had survival rates of 100% at 5 years 145 
and 75% at 10 years. The patients that were 56 to 64 years of age (14, 35%) had a survival 146 
rate of 61.6% at both 5 and 10 years. The patients older than 65 years (18, 45%) had survival 147 
rates of 40.2% at 5 years and 30.2% at 10 years. The difference in the overall survival rates 148 
between the youngest and the oldest cohort was statistically significant (p= 0.03). (Fig. 3).The 149 
eight patients that were between 43 and 55 years of age had a survival rate of 100% at 5 years. 150 
They all underwent an exenteration with a curative aim; 4/8 (50%) underwent a posterior 151 
exenteration, and the other four patients underwent a total exenteration. One patient in this 152 
age range (1/8, 12.5%) underwent a primary exenteration and 7 (7/8, 87.5%) underwent a 153 
secondary exenteration; all 8 patients had complete resection confirmed microscopically. The 154 
tumors were graded G0 (no tumor residual) for 1 patient (1/8, 12.5%), G1 for 1 patient (1/8, 155 
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12.5%), G2 for 2 patients (2/8, 25%) and G3 for 4 patients (4/8, 50%). No patient had 156 
metastasis in the pelvic lymph nodes. One patient had paraaortic lymph node metastasis, and 157 
2 patients had metastases in the mesenteric lymph nodes. 158 
Considering only the homogenous group of the 15 patients with adenocarcinoma who 159 
underwent exenteration with a curative aim and for whom pathological free margins were 160 
achieved, no lymph node metastases were present, and no evidence of lymphangiosis was 161 
observed, we achieved a survival rate of 77.5% at 5 years and of 64.6% at 10 years. 162 
 163 
Complications occurred in 12 of the 40 patients (30%). Seven patients had one complication, 164 
such as abscess formation, ileus, fistula, lymph cyst, septicemia, thrombosis, etc. Two patients 165 
had two complications, and 3 patients had more than two complications. 166 
In this study, which included many elderly patients, the cause of death was local recurrence 167 
for 2 patients and distant metastasis for 5 patients. For 12 patients, the cause of death was not 168 
tumor related. At the time of this publication, 2 patients were still living, and their lung 169 
metastases had been removed. The perioperative mortality rate (30 postoperative days) was 170 
7.5% (3/40).  171 
 172 
Discussion 173 
The main indication for pelvic exenteration is the central persistence or recurrence of 174 
gynecologic cancers. A major issue when comparing published data regarding pelvic 175 
exenterations is the heterogeneity of patient groups. In numerous papers, patients with 176 
different gynecologic cancers are not analyzed separately; therefore, the results of those 177 
papers should be interpreted with caution. The study presented here describes a series of a 178 
single gynecologic cancer entity, endometrial cancer, and solely depicts clinical outcome after 179 
pelvic exenteration. Although many parameters, such as perioperative morbidity and mortality 180 
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rates after pelvic exenteration, are similar between different cancer types, there are some 181 
interesting distinctions that require closer consideration. 182 
The first reported perioperative mortality rate for pelvic exenteration for primary advanced or 183 
recurrent endometrial carcinoma was 23% [1,2], and this has decreased to between 0 and 10% 184 
[3, 4, 5, 6]. In our study, there were no intraoperative deaths, and the perioperative mortality 185 
rate was 7.5%, which is comparable with those reported previously in the literature. 186 
Morbidity rates of up to 75% have been reported by earlier publications [3,6,7,8,9]. Due to 187 
improvement in perioperative care, operative morbidity has noticeably declined over the last 188 
few decades. Our complication rate of 30% is within the reported range for pelvic 189 
exenteration, although 37 of our 40 patients (92%) were pretreated, and the majority of them 190 
were pretreated more than once (24/37, 65%). Regardless of these pretreatments, we achieved 191 
complete continent reconstruction of the neo-bladder and colon in 80% (32/40) of our 192 
patients. Of the initial 18 patients who underwent a protective colostomy, 8 were resected and 193 
10 were maintained due to patient request.  194 
The 5-year overall survival rate of the 40 patients with primary advanced or recurrent 195 
endometrial cancer was 61.4 %. The best outcome was observed in the youngest age group 196 
(43-55 years). All women in that group survived 5 years. For this age group, no advantage 197 
was found in regards to negative prognostic features, such as high grading (G3: 4/8, 50%). 198 
The oldest patient group (>65 years) had a 5-year survival rate of 40.2% and a 10-year 199 
survival rate of 30.2%, which indicates that pelvic exenteration is still a viable option for 200 
these patients, with a long-term survival rate. Furthermore, these data are in accordance with 201 
those of other authors [8, 9 10, 11, 12-17]. 202 
For patients undergoing pelvic exenteration with a curative intent, the survival rate of patients 203 
with primary advanced or recurrent cervical cancer is higher than that of patients with 204 
endometrial cancer: 72.6 % vs. 64% at 5 years and 59.4% vs. 57% at 10 years [25]. However, 205 
due to the small cohort in this study, this difference was not statistically significant (p= 0.70).  206 
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This difference in survival rate may be due to the different biological behaviors (parametrial 207 
vs nodal invasion) of these two cancer entities and once again indicates the problem of 208 
analyzing outcomes after pelvic exenterations in an inhomogeneous cohort. Another observed 209 
difference between endometrial and cervical cancer is the presence of mesorectal lymph node 210 
metastasis without infiltration of the rectum. While mesocolic lymph node metastasis clearly 211 
decreases the 5-year overall survival of patients with cervical cancer [25], this was not found 212 
in patients with endometrial cancer . Of three patients with mesocolic lymph node metastasis, 213 
2 patients experienced long-term survival with no other lymph node metastases, and one 214 
patient died after R1 resection shortly after the operation.  215 
When major symptoms, such as pelvic pain, bowel obstruction and fistula formation, 216 
substantially reduce patient quality of live, palliative exenteration may be considered, not only 217 
to improve quality of live but also to improve survival. In support of this, the patients in our 218 
study who underwent palliative exenteration had a 5-year survival rate of 19.1%. Other 219 
therapy options, such as chemotherapy, radiation and the combination of the two, show 220 
overall survival rates of a few months and sometimes cause severe side effects. In a phase II 221 
trial, patients with persistent or recurrent endometrial cancer receiving bevacizumab had a 222 
median progression free survival of 4.2 months and an overall survival of 10.5 months [26]. 223 
Several other phase II and III trials with single agent chemotherapy showed a limited response 224 
rate that typically lasted for only several months [27]. Due to the lack of alternative effective 225 
treatment options, pelvic exenteration may be a reasonable alternative. 226 
Although patients with primary advanced endometrial cancer represent only a small portion of 227 
patients with newly diagnosed uterine cancers, they have a high percentage of disease-related 228 
deaths, with low survival rates in patients with advanced stage or recurrent disease [18, 19, 229 
20, 21, 23, 26, 27]. Women with advanced stage or recurrent disease are often multimorbid, 230 
obese and older than women with other uterine cancers; thus, frequently, they are not 231 
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considered ideal candidates for extensive surgeries, such as pelvic exenteration, even though 232 
studies have shown that mortality can be decreased when surgery is performed [22].  233 
The limitations of our study are its retrospective character and relatively small cohort. 234 
However, the 40 cases presented here represent the largest patient cohort with advanced or 235 
locally recurrent endometrial cancer who underwent pelvic exenteration published to date. 236 
Generally, papers describing pelvic exenteration often do not include a control group or a 237 
comparison group. Only a few studies have compared pelvic exenteration to radiotherapy, and 238 
we did not find any studies that compared exenteration to chemotherapy. The limited data 239 
available demonstrate that pelvic exenteration may provide some benefit over radiation, 240 
although larger studies are necessary to support his finding [24].  241 
Improvements in operative technique have resulted in the more frequent achievement of 242 
pathological free margins. There are limited treatment options available for women with 243 
advanced or recurrent endometrial cancer, and exenteration is the only treatment that provides 244 
the possibility of cure. Our finding of a five-year overall survival rate of 61.4 % supports the 245 
findings of other authors, who also showed high survival rates when pathologically free 246 
margins are achieved. 247 
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Fig. 1: Overall survival after pelvic exenteration in patients with primary advanced or 365 
recurrent endometrial cancer (Kaplan–Meier curve). 366 
 367 
Fig. 2: Overall survival after pelvic exenteration in patients according to curative or 368 
palliative aim (Kaplan–Meier curves). 369 
 370 
Fig. 3: Overall survival after pelvic exenteration according to age group (Kaplan–371 
Meier curves). 372 
 373 
Tabl.: 1 General demographics 374 
 375 





General demographics for the cohort  
 
General demographics  
Age 43-55 years 8 
Age 56-64 years 14 
Age >65 years 18 
Obesity 2 
Diabetes 2 
Vascular diseases 4 
Others or combination of diseases named above 4 
  
Curative exenteration 31 
Palliative exenteration 9 
Primary exenteration 3 
Secondary exenteration 37 
  
Interval pretreatment/exenteration  
After initial operation (12 patients) Min. 4 months, max. 86 months, median 23 
months 
After initial radiation (1 patient) 13 months, median 13 months 



















None 3  0 3 2 2 2 
Operation 12 Not performed 7 0 11 11 3 2 
Performed, 
missing report 1 
Tumor-free 3 
Metastasis  1 




24 Not performed 16 2 20 19 4 4 
Tumor-free 6 
Metastasis 2 
 
Table: 2 
